According to the invention the approach of an easy risk assessment of patients with diagnosed cardiac insufficiency is based on the measurement of concentration of a pro-tein in whole blood called MD-2 by using the ELISA-technology. ELISA (Enzyme-Linked-Immunosorbent-Assay) is a common and standardized immunological assay for the detection of specific molecules in body liq-uids. It is well known that for cardiac degen-eration the activation of toll-like receptor-4 (TLR 4) is important. TLR 4 and MD-2 then form a receptor complex. By the additional use of MD-2 biomarker to the gold-standard biomarker BNP for risk stratification of cardiac insufficiency, an in-crease of sensitivity and specificity regarding to the long-term survival can be realized. The used biomarker for this assay, is a MD-2 protein (also called LY96) which relates to the group of so-called Immune response receptors.
Further information: PDF
PVA Mecklenburg-Vorpommern AG
Phone: +49 (0)381 49747-38
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
email@example.com | TechnologieAllianz e.V.
New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.
Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.
21.07.2017 | Event News
19.07.2017 | Event News
12.07.2017 | Event News
21.07.2017 | Earth Sciences
21.07.2017 | Power and Electrical Engineering
21.07.2017 | Physics and Astronomy